Trajan Acquires Grale Scientific

Trajan Acquires Grale Scientific

February 28, 2012

Trajan Scientific and Medical has acquired the business of Grale Scientific. Grale, established in 1983, is a leading supplier of pathology consumables and services, based in Melbourne, Victoria, Australia. Stephen Tomisich, Director of the Trajan Group said “Grale is an ideal launching pad for Trajan in Victoria. It’s a great business built around personalized service to pathology laboratories; a strength we intend to build upon.”

The product range of Grale Scientific includes specimen containers, cutting/preparation tools, a broad range of microscope slides, coverslips, reagent products and storage solutions.

Trajan was established in August 2011 with a charter to work with, develop and invest in scientific and medical businesses.




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More